Tempest Gross Profit from 2010 to 2025

TPST Stock

USD 0.93 0.03 3.33%

Tempest Therapeutics Gross Profit yearly trend continues to be comparatively stable with very little volatility. Gross Profit will likely drop to about -360 K in 2025. Gross Profit is the profit Tempest Therapeutics makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. View All Fundamentals

Gross Profit

First Reported

2014-12-31

Previous Quarter

-88 K

Current Value

-155 K

Quarterly Volatility

2 M

Yuan Drop

Covid

Check Tempest Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Tempest Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 416.2 K, Interest Expense of 1.7 M or Selling General Administrative of 15.4 M, as well as many indicators such as Price To Sales Ratio of 1.36, Dividend Yield of 0.0 or PTB Ratio of 3.14. Tempest financial statements analysis is a perfect complement when working with Tempest Therapeutics Valuation or Volatility modules.

Check out the analysis of Tempest Therapeutics Correlation against competitors.

For more information on how to buy Tempest Stock please use our How to Invest in Tempest Therapeutics guide.

Latest Tempest Therapeutics' Gross Profit Growth Pattern

Below is the plot of the Gross Profit of Tempest Therapeutics over the last few years. Gross profit is a required income statement account that reflects total revenue of Tempest Therapeutics minus its cost of goods sold. It is profit before Tempest Therapeutics operating expenses, interest payments and taxes. Gross profit is also known as gross margin. It is the profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. Tempest Therapeutics' Gross Profit historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Tempest Therapeutics' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 0

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Gross Profit

Timeline

Tempest Gross Profit Regression Statistics

	Arithmetic Mean	2,148,316
	Coefficient Of Variation	250.63
	Mean Deviation	4,741,678
	Median	(381,000)
	Standard Deviation	5,384,284
	Sample Variance	29T
	Range	14.5M
	R-Value	(0.73)
	Mean Square Error	14.7T
	R-Squared	0.53
	Significance	0
	Slope	(821,139)
	Total Sum of Squares	434.9T

Tempest Gross Profit History

	2025	-360 K
	2024	-342.9 K
	2023	-381 K
	2022	-1.8 M
	2021	-1.3 M
	2020	-815 K

Other Fundumenentals of Tempest Therapeutics

Gross Profit Margin

Tempest Therapeutics Gross Profit component correlations

	Total Assets	Net Debt	Retained Earnings	Total Liab	Total Current Assets	Total Stockholder Equity	Accounts Payable	Short Term Investments	Common Stock	Current Deferred Revenue	Net Receivables	Short Term Debt	Net Tangible Assets	Property Plant Equipment	Net Invested Capital	Capital Stock	Net Working Capital	Long Term Debt	Short Long Term Debt
Total Assets		-0.66	-0.72	-0.17	0.99	0.78	0.77	0.62	0.56	-0.06	0.13	0.01	0.02	0.13	0.0	-0.01	0.05	0.05	-0.06
Net Debt	-0.66		0.49	0.07	-0.69	-0.5	-0.41	-0.08	-0.09	-0.13	-0.15	0.12	0.18	0.08	0.18	0.21	0.07	-0.24	-0.13
Retained Earnings	-0.72	0.49		0.03	-0.7	-0.48	-0.48	-0.34	-0.68	0.11	0.11	-0.19	-0.13	-0.17	-0.11	-0.16	-0.05	0.17	0.11
Total Liab	-0.17	0.07	0.03		-0.2	-0.71	-0.29	-0.35	-0.25	-0.07	0.03	0.24	0.15	-0.28	0.26	0.17	0.27	-0.15	-0.07
Total Current Assets	0.99	-0.69	-0.7	-0.2		0.8	0.8	0.64	0.55	-0.04	0.16	-0.07	-0.06	0.05	-0.08	-0.09	0.0	0.15	-0.04
Total Stockholder Equity	0.78	-0.5	-0.48	-0.71	0.8		0.73	0.71	0.55	0.09	0.11	-0.24	-0.16	0.19	-0.23	-0.21	-0.18	0.22	0.09
Accounts Payable	0.77	-0.41	-0.48	-0.29	0.8	0.73		0.84	0.63	0.17	-0.05	-0.45	-0.43	-0.27	-0.46	-0.41	-0.42	0.41	0.17
Short Term Investments	0.62	-0.08	-0.34	-0.35	0.64	0.71	0.84		0.79	0.25	-0.03	-0.51	-0.46	-0.22	-0.49	-0.43	-0.44	0.4	0.25
Common Stock	0.56	-0.09	-0.68	-0.25	0.55	0.55	0.63	0.79		0.08	-0.3	-0.2	-0.3	-0.09	-0.33	-0.13	-0.37	0.06	0.08
Current Deferred Revenue	-0.06	-0.13	0.11	-0.07	-0.04	0.09	0.17	0.25	0.08		0.21	-0.73	-0.56	-0.4	-0.55	-0.76	-0.44	0.61	1.0
Net Receivables	0.13	-0.15	0.11	0.03	0.16	0.11	-0.05	-0.03	-0.3	0.21		-0.07	0.18	0.14	0.24	-0.17	0.56	0.33	0.21
Short Term Debt	0.01	0.12	-0.19	0.24	-0.07	-0.24	-0.45	-0.51	-0.2	-0.73	-0.07		0.91	0.7	0.9	0.97	0.77	-0.92	-0.73
Net Tangible Assets	0.02	0.18	-0.13	0.15	-0.06	-0.16	-0.43	-0.46	-0.3	-0.56	0.18	0.91		0.8	0.99	0.89	0.88	-0.83	-0.56
Property Plant Equipment	0.13	0.08	-0.17	-0.28	0.05	0.19	-0.27	-0.22	-0.09	-0.4	0.14	0.7	0.8		0.74	0.71	0.67	-0.72	-0.4
Net Invested Capital	0.0	0.18	-0.11	0.26	-0.08	-0.23	-0.46	-0.49	-0.33	-0.55	0.24	0.9	0.99	0.74		0.88	0.92	-0.8	-0.55
Capital Stock	-0.01	0.21	-0.16	0.17	-0.09	-0.21	-0.41	-0.43	-0.13	-0.76	-0.17	0.97	0.89	0.71	0.88		0.7	-0.96	-0.76
Net Working Capital	0.05	0.07	-0.05	0.27	0.0	-0.18	-0.42	-0.44	-0.37	-0.44	0.56	0.77	0.88	0.67	0.92	0.7		-0.57	-0.44
Long Term Debt	0.05	-0.24	0.17	-0.15	0.15	0.22	0.41	0.4	0.06	0.61	0.33	-0.92	-0.83	-0.72	-0.8	-0.96	-0.57		0.61
Short Long Term Debt	-0.06	-0.13	0.11	-0.07	-0.04	0.09	0.17	0.25	0.08	1.0	0.21	-0.73	-0.56	-0.4	-0.55	-0.76	-0.44	0.61

Click cells to compare fundamentals

About Tempest Therapeutics Financial Statements

Tempest Therapeutics shareholders use historical fundamental indicators, such as Gross Profit, to determine how well the company is positioned to perform in the future. Although Tempest Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Tempest Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Tempest Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

	Last Reported	Projected for Next Year
Gross Profit	-342.9 K	-360 K
Gross Profit Margin	0.81	0.86

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Tempest Stock Analysis

When running Tempest Therapeutics' price analysis, check to measure Tempest Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tempest Therapeutics is operating at the current time. Most of Tempest Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tempest Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tempest Therapeutics' price. Additionally, you may evaluate how the addition of Tempest Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC